Intravesikale Radioimmuntherapie des Carcinoma in situ der Harnblase nach BCG-Versagen

M. E. Autenrieth; T. Horn; F. Kurtz; K. Nguyen; A. Morgenstern; F. Bruchertseifer; M. Schwaiger; M. Blechert; C. Seidl; R. Senekowitsch-Schmidtke; J. E. Gschwend; K. Scheidhauer

doi:10.1007/s00120-016-0273-4

Intravesikale Radioimmuntherapie des Carcinoma in situ der Harnblase nach BCG-Versagen

Translated title of the contribution: Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure

M. E. Autenrieth
, T. Horn
, F. Kurtz
, K. Nguyen
, A. Morgenstern
, F. Bruchertseifer
, M. Schwaiger
, M. Blechert
, C. Seidl
, R. Senekowitsch-Schmidtke
, J. E. Gschwend
, K. Scheidhauer

Technical University of Munich
European Commission Joint Research Centre

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Background: In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure. Objectives: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure. Materials and methods: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation. Results: All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients. Conclusions: Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder.

Translated title of the contribution	Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure
Original language	German
Pages (from-to)	40-43
Number of pages	4
Journal	Urologe - Ausgabe A
Volume	56
Issue number	1
DOIs	https://doi.org/10.1007/s00120-016-0273-4
State	Published - 1 Jan 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00120-016-0273-4

Cite this

@article{3c40d31fbe644aac85fd3cfc832d2ecb,

title = "Intravesikale Radioimmuntherapie des Carcinoma in situ der Harnblase nach BCG-Versagen",

abstract = "Background: In failure to respond to bacillus Calmette-Gu{\'e}rin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure. Objectives: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure. Materials and methods: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation. Results: All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients. Conclusions: Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder.",

keywords = "Cystectomy, radical, Instillation, bladder, Radioimmunotherapy, Resection, transurethral, Tumor recurrence",

author = "Autenrieth, \{M. E.\} and T. Horn and F. Kurtz and K. Nguyen and A. Morgenstern and F. Bruchertseifer and M. Schwaiger and M. Blechert and C. Seidl and R. Senekowitsch-Schmidtke and Gschwend, \{J. E.\} and K. Scheidhauer",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Medizin Verlag Berlin.",

year = "2017",

month = jan,

day = "1",

doi = "10.1007/s00120-016-0273-4",

language = "Deutsch",

volume = "56",

pages = "40--43",

journal = "Urologe - Ausgabe A",

issn = "0340-2592",

publisher = "Springer Medizin",

number = "1",

}

TY - JOUR

T1 - Intravesikale Radioimmuntherapie des Carcinoma in situ der Harnblase nach BCG-Versagen

AU - Autenrieth, M. E.

AU - Horn, T.

AU - Kurtz, F.

AU - Nguyen, K.

AU - Morgenstern, A.

AU - Bruchertseifer, F.

AU - Schwaiger, M.

AU - Blechert, M.

AU - Seidl, C.

AU - Senekowitsch-Schmidtke, R.

AU - Gschwend, J. E.

AU - Scheidhauer, K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure. Objectives: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure. Materials and methods: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation. Results: All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients. Conclusions: Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder.

AB - Background: In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure. Objectives: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure. Materials and methods: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation. Results: All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients. Conclusions: Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder.

KW - Cystectomy, radical

KW - Instillation, bladder

KW - Radioimmunotherapy

KW - Resection, transurethral

KW - Tumor recurrence

UR - https://www.scopus.com/pages/publications/84996931227

U2 - 10.1007/s00120-016-0273-4

DO - 10.1007/s00120-016-0273-4

M3 - Artikel

C2 - 27885456

AN - SCOPUS:84996931227

SN - 0340-2592

VL - 56

SP - 40

EP - 43

JO - Urologe - Ausgabe A

JF - Urologe - Ausgabe A

IS - 1

ER -

Intravesikale Radioimmuntherapie des Carcinoma in situ der Harnblase nach BCG-Versagen

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this